Skip to main content
Premium Trial:

Request an Annual Quote

FDA to Use Ariana for Genomic Data Tools

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Ariana Pharma will provide its biomarker data mining technology to the US Food and Drug Administration for its efforts to develop better tools for analyzing genomic data to be used in personalized medicine.

Under a collaborative agreement, FDA will use Ariana's KEM Biomarker technology to analyze data combined with patient characteristics for biomarker signatures that were submitted to FDA through its Voluntary Exploratory Data Submission program, the Paris-based company said today.

"We are looking forward to this collaboration to help the agency systematically analyze all equivalent signatures combining both genomic and phenotypical data," Federico Goodsaid, associate director for operations in genomics in the Office of Clinical Pharmacology at the Center for Drug Evaluation and Research at the FDA, said in a statement.

Ariana Pharma's KEM platform mines and extracts data and enables researchers to make decisions that involve multiple criteria and objectives, the company said.

The Scan

Transplant Tests Edited Pig Kidneys

The Associated Press reports a University of Alabama-Birmingham team transplanted genetically modified pig kidneys into a brain-dead human patient.

UK Changes Some Gene-Edited Crop Rules

A new law may enable gene-edited crops to be sold in the UK within about five years, New Scientist says.

Pill Works Against Omicron in Lab

Pfizer's antiviral pill to treat SARS-CoV-2 appears to work against the Omicron variant, the Wall Street Journal reports.

Nature Papers Find Genetic Risk Factor for Smell, Taste Loss in COVID-19; Analyze TB Granulomas

In Nature this week: genome-wide association study find locus linked to the risk COVID-19 patients losing their sense of taste or smell, and more.